However in certain sarcomas, VEGF-A pathway inhibition can increase intratumoral hypoxia and HIF-1α activity, which in turn leads to increased tumor formation and metastasis via upregulation of effectors such as PLOD2 and FOXM1 [16–18]. Here, VEGFA is linked to sarcoma.